Bridgefront Capital LLC Has $1.08 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Bridgefront Capital LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 52.6% in the fourth quarter, Holdings Channel reports. The firm owned 5,845 shares of the medical research company’s stock after purchasing an additional 2,014 shares during the quarter. Bridgefront Capital LLC’s holdings in Charles River Laboratories International were worth $1,079,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CRL. Veracity Capital LLC acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $589,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Charles River Laboratories International by 46.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock valued at $987,000 after purchasing an additional 1,679 shares in the last quarter. Boston Trust Walden Corp boosted its stake in Charles River Laboratories International by 4.3% in the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company’s stock worth $37,748,000 after purchasing an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its holdings in shares of Charles River Laboratories International by 225.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company’s stock worth $480,000 after purchasing an additional 1,800 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $118.33 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company’s fifty day simple moving average is $141.89 and its 200-day simple moving average is $168.28. The firm has a market cap of $5.81 billion, a PE ratio of 788.87, a P/E/G ratio of 4.54 and a beta of 1.50. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.46 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity

In related news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Finally, Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $182.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).